Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 4/20 | 0.33 |
| ▸ | HTR1A | P08908 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26759929 | 0.85 | MEN1 (0.35) | MEN1KMT2ACRBN | |
| SCHEMBL26346649 | 0.81 | MEN1 (0.31) | MEN1KMT2ACRBN | |
| SCHEMBL26759938 | 0.79 | GLP1R (0.38) | — | |
| SCHEMBL13695975 | 0.75 | CRBN (0.36) | MEN1KMT2ACRBN | |
| SCHEMBL27109254 | 0.72 | KMT2A (0.53) | MEN1KMT2ACRBN | |
| SCHEMBL22957224 | 0.71 | MEN1 (0.41) | MEN1KMT2ACRBN | |
| SCHEMBL13695954 | 0.71 | MEN1 (0.41) | MEN1KMT2ACRBN | |
| SCHEMBL18313748 | 0.70 | MEN1 (0.49) | ADRB2HTR1AMEN1KMT2A | |
| SCHEMBL18886281 | 0.70 | CRBN (0.41) | MEN1KMT2ACRBN | |
| SCHEMBL17282361 | 0.70 | CRBN (0.41) | MEN1KMT2ACRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357342-A1 | MODIFIED IL-18 POLYPEPTIDES | BRIGHT PEAK THERAPEUTICS AG (CH) | 2023-11-09 | — | — | US | disclosed |
| US-20230355795-A1 | IMMUNE ANTIGEN SPECIFIC IL-18 IMMUNOCYTOKINES AND USES THEREOF | BRIGHT PEAK THERAPEUTICS AG (CH) | 2023-11-09 | — | — | US | disclosed |
| US-20230357342-A1 | MODIFIED IL-18 POLYPEPTIDES | BRIGHT PEAK THERAPEUTICS AG (CH) | 2023-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230355795-A1 | IMMUNE ANTIGEN SPECIFIC IL-18 IMMUNOCYTOKINES AND USES THEREOF | IL18, CD74, IL2 | ADRB2 4785/4885HTR1A 4792/4885MEN1 3006/4885 |
| US-20230357342-A1 | MODIFIED IL-18 POLYPEPTIDES | IL18, IL2, IL36G | ADRB2 4450/4885HTR1A 4185/4885MEN1 2596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.